ARCA biopharma, Inc. (ABIO) financial statements (2021 and earlier)

Company profile

Business Address 10170 CHURCH RANCH WAY
WESTMINSTER, CO 80021
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments498712213915
Cash and cash equivalents4987973915
Short-term investments   314  
Other current assets1001000
Total current assets:508712213915
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment0000000
Long-term investments and receivables    2  
Long-term investments    2  
Other noncurrent assets0000111
Total noncurrent assets:0000311
TOTAL ASSETS:509712254016
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3112221
Accounts payable2001101
Accrued liabilities100100 
Employee-related liabilities1001110
Other liabilities      0
Total current liabilities:3112221
Noncurrent Liabilities
Long-term debt and lease obligation0      
Operating lease, liability0 
Liabilities, other than long-term debt   00 0
Deferred revenue and credits00 0
Other undisclosed noncurrent liabilities(0)      
Total noncurrent liabilities:0  00 0
Total liabilities:4112221
Stockholders' equity
Stockholders' equity attributable to parent478610223815
Common stock0000000
Additional paid in capital20115214514113513499
Accumulated other comprehensive loss   (0)(0)  
Accumulated deficit(154)(144)(139)(131)(113)(96)(85)
Total stockholders' equity:478610223815
TOTAL LIABILITIES AND EQUITY:509712254016

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(10)(6)(8)(19)(17)(11)(10)
Other undisclosed operating income      0
Operating loss:(10)(6)(8)(19)(17)(11)(10)
Interest and debt expense(0)(0)(0)(0) (0)(0)
Loss from continuing operations before equity method investments, income taxes:(10)(6)(8)(19)(17)(11)(10)
Other undisclosed income from continuing operations before income taxes0000   
Loss from continuing operations before income taxes:(10)(6)(8)(19)(17)(11)(10)
Income tax benefit0000   
Net loss:(10)(5)(8)(18)(17)(11)(10)
Other undisclosed net income attributable to parent    000
Net loss available to common stockholders, diluted:(10)(5)(8)(18)(16)(11)(10)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(10)(5)(8)(18)(17)(11)(10)
Comprehensive loss:(10)(5)(8)(18)(17)(11)(10)
Other undisclosed comprehensive income, net of tax, attributable to parent  000  
Comprehensive loss, net of tax, attributable to parent:(10)(5)(8)(18)(16)(11)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: